HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Experts Support Statin, Triptan, Sleep Aid Switches In New Paradigm

This article was originally published in The Tan Sheet

Executive Summary

The American Society of Health-System Pharmacists has opposed allowing OTC sales of statins, but would support a switch made with conditions of safe use required. A Philadelphia College of Pharmacy professor argues that patients are better served by obtaining pharmaceuticals from health care professionals than using “un-standardized” dietary supplements

You may also be interested in...

Sanofi Licenses OTC Tamiflu From Roche To Attempt First US Flu Treatment Switch

Sanofi consumer health chief Alan Main says with the US the largest OTC drug market, a successful switch for Tamiflu, marketed in the US by Roche subsidiary Genentech, would support the firm's global strategy for expanding cough and cold remedy sales.

Support Rises For Red Yeast Extract As Alternative To Statin Therapy

Red yeast extract could be a treatment option to lower cholesterol in patients who cannot tolerate statin therapy, according to an Annals of Internal Medicine study

FDA Panel To Influenza Home MedKit Sponsors: Get Real

Roche begins label comprehension studies this month to support development of aTamiflu home MedKit for the treatment or prophylaxis of pandemic influenza virus, under an initiative driven by the Department of Health and Human Services

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts